Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
GH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.14 - $68.00
Previous CloseN/A
Volume639.07K
Average Volume (3M)2.50M
Market Cap
$7.73B
Enterprise Value$7.16B
Total Cash (Recent Filing)$629.14M
Total Debt (Recent Filing)$1.33B
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Oct 30, 2025EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding124,705,860
10 Day Avg. Volume2,764,463
30 Day Avg. Volume2,500,389
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue8.64
Enterprise Value/Gross Profit13.75
Enterprise Value/Ebitda-19.45
Forecast
1Y Price Target
$68.45Price Target Upside10.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
Bulls Say, Bears Say
Bulls Say
Product LaunchThe launch of new and innovative products, such as the Reveal Ultra test and Shield MCED test, showcases Guardant Health's commitment to advancing its product offerings.
Revenue GrowthGuardant Health announced it would launch Shield for multi-cancer detection and expects at least $500 million in annual revenue from the asset by 2028.
Technology And InnovationGuardant Health leverages its InfinityAI learning engine to analyze extensive multiomics data, with an estimated addressable market of $300 billion for multi-disease screening.
Bears Say
Market ExpectationsInvestors were expecting an increase to the long-range plan for SHIELD CRC/MCD, which did not happen.
Volume ConcernsShield revenue guidance - which has been arguably the biggest focus - remained in place with higher price though lower volumes.
Guardant Health News
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $20.14 and its highest was $68.00 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $7.73B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Oct 30, 2025 which is in 29 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Jul 30, 2025. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.741 by -$0.059.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.79.
How many shares outstanding does Guardant Health have?
Guardant Health has 124,705,860 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.741. Following the earnings report the stock price went down -9.316%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in GH
Guardant Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$68.45 (10.42% Upside)
$68.45 (10.42% Upside)
Blogger Sentiment
Bullish
GH Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $18.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
170.93%
12-Months-Change
Fundamentals
Return on Equity
-4584.47%
Trailing 12-Months
Asset Growth
-17.23%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
GH Company Deck
GH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong quarter for Guardant Health with significant revenue growth, successful product launches, and improved gross margins. Despite some uncertainties regarding the timing of Shield V2 data and Medicare reimbursement processes, the company's strong performance and raised revenue guidance indicate a positive outlook.View all GH earnings summariesGH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
GH Stock 12 Month Forecast
Average Price Target
$68.45
▲(10.42% Upside)
Technical Analysis
Ownership Overview
3.60% Insiders
29.88% Mutual Funds
39.42% Other Institutional Investors
11.39% Public Companies and Individual Investors